A Randomized Two-by-Two Multicenter Open-Label Phase III Study of BMS-354825 Administered Orally at a Dose of 50 mg or 70 mg Twice Daily or 100 mg or 140 mg Once Daily in Subjects with Chronic Phase Philadelphia Chromosome or BCR-ABL Positive Chronic My
-
- STATUS
- Not Recruiting
Summary
The purpose of this study is to assess the effectiveness of an investigational drug (BMS-354825) given at two different total daily doses according to two different schedules (i.e. once daily at 100 milligrams (mg) or 140 mg or twice daily at 50 mg or 70
Description
The purpose of this study is to assess the effectiveness of an investigational drug (BMS-354825) given at two different total daily doses according to two different schedules (i.e. once daily at 100 milligrams (mg) or 140 mg or twice daily at 50 mg or 70
Details
| Age | 18years - 100years |
|---|---|
| Clinical Study Identifier | TX1540 |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.